An Evaluation of Dirlotapide (Slentrol®) in Obese and Overweight, Client-owned Dogs in Two Placebo-controlled Clinical Studies in Europe
World Small Animal Veterinary Association World Congress Proceedings, 2007
J. Gossellin1; J. McKelvie1; J. Sherington1; J.A. Wren2; J.S. Eagleson3; T.G. Rowan1; S.J. Sunderland1
1Veterinary Medicine Research and Development, Pfizer Ltd., Sandwich, Kent, UK; 2Veterinary Medicine Research and Development, Pfizer Inc., Kalamazoo, MI, USA; 3Veterinary Medicine Pharmaceutical Sciences, Pfizer Pharmaceuticals (Pvt) Limited, Navi Mumbai, India

Background

Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor developed to treat obesity in dogs.

Aims

To evaluate the efficacy and clinical safety of dirlotapide for weight reduction in overweight, adult dogs presenting at veterinary clinics in two masked, multi-centre studies (A and B) with parallel designs.

Methods

Overweight dogs (245 of various breeds) were randomised to treatment with dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered orally once daily at an initial dose of 0.05 mg/kg/day and doubled after 14 days. Dogs were examined, weighed, body condition scores (BCS) were recorded, and dosage was adjusted individually for each patient every 28 days until ideal BCS was attained or for up to 196 days. Owners maintained pre-treatment feeding regimens.

Results

During treatment for up to 196 days, dirlotapide and placebo-treated dogs showed respective mean weight losses of 15.9% and 5.3% (A) and 14.0% and 1.7% (B). Percentage weekly weight losses for dirlotapide were significantly (P<0.0002) greater than for placebo: 0.76% vs. 0.24% (A); 0.70% vs. 0.09% (B). After 196 days, dirlotapide-treated dogs showed mean weight losses of 20.9% (A) and 18.4% (B). Emesis and diarrhoea were experienced in both treatments but were more frequent with dirlotapide. At study completion, mean dirlotapide dosage were 0.38 (A) and 0.29 (B) mg/kg initial body weight/day.

Conclusion

Dirlotapide was found to be clinically safe and effective in the reduction of body weight in overweight dogs fed a variety of diets.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Jacques Gossellin
Pfizer Ltd - Veterinary Medicine Research and Development
Kent, United Kingdom


MAIN : Abstracts - Oral : Evaluation of Dirlotapide
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27